HOME >> MEDICINE >> NEWS
The Molecular Profiling Institute, Inc. and IBM advance technology

The Molecular Profiling Institute, Inc. (Molecular Profiling) announced today that its alliance with IBM on the Healthcare Life Sciences Collaboration Project is generating tools that allow for improved personalized medicine offerings and better patient care.

As a result of the collaboration, Molecular Profiling anticipates being able to offer to physicians, in conjunction with their ordering of diagnostic tests from Molecular Profiling, a Personalized Medicine Expert System (PerMedEx). PerMedEx is a sophisticated, proprietary system that allows physicians a high throughput reporting structure to better apply genomic advances to the practice of medicine. The system allows for a more tailored treatment strategy and enhanced reporting, follow-up and more holistic management of the patient's condition.

"The goal of the Molecular Profiling Institute is to give physicians the tools they need to provide a greater level of personalized medicine in the treatment of their patients," said Dr. Robert J. Penny, the president and CEO of Molecular Profiling. "Our alliance with IBM should allow Molecular Profiling to offer physicians a tailored medical strategy for their individual patients."

IBM and Molecular Profiling's joint effort to create a CDI solution is aimed at helping battle cancer by combining IBM's hardware/software expertise and MPI's genomics/clinical expertise. At this stage in the development, Molecular Profiling provides clinical data, modeling, and system testing. Molecular Profiling is also designing and building a Clinical Information Management System (CIMS) and genomic analytic software (GAS), along with synonym and taxonomy dictionaries. IBM's focus on this phase of this project is principally on the development of the infrastructure of CDI, including data repositories, knowledge management, workflow management and user interfaces.

"The industry is aware of the benefits of incorporating informatics capabilities int
'"/>

Contact: Dr. Robert Penny
rpenny@molecularprofiling.com
602-358-8901
The Translational Genomics Research Institute
8-Nov-2005


Page: 1 2 3

Related medicine news :

1. Elsevier launches Molecular Oncology
2. Molecular marker may help identify pancreatic cancer, and possibly predict survival time
3. Molecular differences between early and advanced melanomas could provide new drug targets
4. Molecular structure reveals how botulinum toxin attaches to nerve cells
5. Molecular medicine comes to the rescue
6. Molecular switch may turn off immune cells that target HIV
7. Molecular imaging may lead to earlier diagnosis of childhood respiratory virus
8. Molecular Profiling Institute secures $7.5 million in Series B funding
9. Molecular studies in cancer of the colon
10. Molecular ballet unravels, links proteins so cell can direct own movement
11. Molecular testing in patients with rare cancer predicts response to Gleevec

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: The Molecular Profiling Institute Inc and IBM advance technology

(Date:10/22/2014)... 2014 On Saturday, October 25, 2014, the ... family health and fitness fair ¡Vive tu vida! Get Up! ... good nutrition for better health and wellness for people of ... and open to the public, will be held at Dean ... am to 1:00 pm. , “¡Vive tu Vida! Get ...
(Date:10/22/2014)... 2014 Isabel Healthcare will ... Professions (ASAHP) Conference on October 22-24 in Las Vegas, ... in a panel discussion on Technology in Health Professions ... provides a diagnostic decision support tool and clinical education ... of students and clinical learners. The Isabel tools help ...
(Date:10/22/2014)... (HealthDay News) -- The United States is now ... nations of West Africa land at one of ... with the virus. In a statement released ... 94 percent of air passengers from Guinea, Liberia ... these five airports -- New York City,s Kennedy ...
(Date:10/22/2014)... California (PRWEB) October 22, 2014 Hay House ... Move Beyond Addiction and Upgrade Your Life (Paperback; $10.82) written ... of Yoga & Recovery. This book is meant to ... in a life of recovery. , Recovery 2.0 is ... 12 Steps; Recovery 2.0 is a guide for what comes ...
(Date:10/22/2014)... 22, 2014 Best Cheap Hosting USA ... world. The site has recently announced that iPower ( ... for people from around the world. , “iPower is ... today and is providing various kinds of useful products ... insists on offering excellent customer service and a number ...
Breaking Medicine News(10 mins):Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, October ... complimentary registration available at: http://bit.ly/1yStiU9 ... Vidyasekar and Visionary Innovation Research Group Senior ... electricity, self-assembling materials, nanobots and flexible electronics ... will transform our lives in the coming ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
(Date:10/20/2014)... , Oct. 20, 2014  Luoxis Diagnostics, ... MKT: AMPE), today announced that its academic collaborators ... and research potential for its novel RedoxSYS Diagnostic ... (ORP) in the body in response to injury ... of ORP as a clinical marker will be ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
Cached News: